期刊
CELL METABOLISM
卷 29, 期 1, 页码 18-26出版社
CELL PRESS
DOI: 10.1016/j.cmet.2018.10.012
关键词
-
资金
- National Health and Medical Research Council (NHMRC) [APP112227]
- NIH [R01AI043477, R01CA118165, R01CA127923, R01CA155120, R01CA198103, R01CA211794, P42ES010337, P30DK063491, U01AA022614, U01AA027681]
- Southern California Research Center for ALPD & Cirrhosis - National Institute on Alcohol Abuse and Alcoholism [P50AA011999]
Hepatocellular carcinoma (HCC) is one of the most fatal and fastest-growing cancers. Recently, non-alcoholic steatohepatitis (NASH) has been recognized as a major HCC catalyst. However, it is difficult to decipher the molecular mechanisms underlying the pathogenesis of NASH and understand how it progresses to HCC by studying humans. Progress in this field depends on the availability of reliable preclinical models amenable to genetic and functional analyses and exhibiting robust NASH-to-HCC progression. Although numerous mouse models of NASH have been described, many do not faithfully mimic the human disease and few reliably progress to HCC. Here, we review current literature on the molecular etiology of NASH-related HCC and critically evaluate existing mouse models and their suitability for studying this malignancy. We also compare human transcriptomic and histopathological profiles with data from MUP-uPA mice, a reliable model of NASH-driven HCC that has been useful for evaluation of HCC-targeting immuno-therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据